Efficacy of Direct Oral Anticoagulants (DOAC) in antithrombotic therapy for patients with non-valvular atrial fibrillation.
Abstract
The objective of this study is to analyze the characteristics of direct oral anticoagulants (DOACs) and determine which of them is the most appropriate according to the clinical characteristics of each patient. For this, an exhaustive search was carried out in MEDLINE through the PUBMED database, using terms such as "DOACs", "treatment of AF with DOACs", "antithrombotic treatment of atrial fibrillation", "direct oral anticoagulants", "dabigatran", "rivaroxaban" and "apixaban". The results obtained revealed that DOACs reduce the bleeding rate in patients requiring anticoagulation, and apixaban showed the lowest rate of bleeding and cardiovascular complications. In conclusion, a rigorous analysis is required to determine the most appropriate DOAC in each case.
References
Dogliotti, A., Paolasso, E., & Giugliano, R. P. (2013). Novel oral anticoagulants in atrial fibrillation: a meta‐analysis of large, randomized, controlled trials vs warfarin. Clinical Cardiology, 36(2), 61-67.
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011). Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124(14), 1573- 1579.
Eikelboom, J. W., & Weitz, J. I. (2010). New anticoagulants. Circulation, 121(13), 1523-1532.
Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical pharmacokinetics, 48, 1-22.
Frost, C. E., Byon, W., Song, Y., Wang, J., Schuster, A. E., Boyd, R. A., ... & LaCreta, F. (2015). Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor X an inhibitor. British journal of clinical pharmacology, 79(5), 838-846.
Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., & Sandmann, S. (2011). In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. Journal of Pharmacology and Experimental Therapeutics, 338(1), 372-380.
Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A. M., Emmerich, J., ... & Samama, C. M. (2012). Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. The Journal of the American Society of Anesthesiologists, 116(1), 94-102.
Hashimoto, H., Toide, K., Kitamura, R., Fujita, M., Tagawa, S., Itoh, S., & Kamataki, T. (1993). Gene structure of CYP3A4, an adult‐specific form of cytochrome P450 in human livers, and its transcriptional control. European journal of biochemistry, 218(2), 585-595.
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., ... & Kirchhof, P. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15(5), 625-651.
Johansson, S., Cullberg, M., Eriksson, U. G., Elg, M., Dunér, K., Jensen, E., ... & Wåhlander, K. (2011). Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. International Journal of Clinical Pharmacology and Therapeutics, 49(4), 258-267.
Kubitza, D., & Haas, S. (2006). Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert opinion on investigational drugs, 15(8), 843-855.
Mueck, W., Kubitza, D., & Becka, M. (2013). Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British journal of clinical pharmacology, 76(3), 455-466.
Ogata, K., Mendell‐Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., & Kunitada, S. (2010). Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. The Journal of Clinical Pharmacology, 50(7), 743-753.
Pinto, D. J., Orwat, M. J., Koch, S., Rossi, K. A., Alexander, R. S., Smallwood, A., ... & Lam, P. Y. (2007). Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Journal of medicinal chemistry, 50(22), 5339-5356.
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., ... & Zhang, D. (2009). Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug metabolism and disposition, 37(1), 74-81.
Scaglione, F. (2013). New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clinical pharmacokinetics, 52, 69-82.
Shapiro, L. E., & Shear, N. H. (2002). Drug interactions: proteins, pumps, and P-450s. Journal of the American Academy of Dermatology, 47(4), 467-488.
Stangier, J. (2008). Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical pharmacokinetics, 47, 285-295.
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British journal of clinical pharmacology, 64(3), 292-303.
Stöllberger, C., & Finsterer, J. (2015). Relevanz von P-Glykoprotein in der schlaganfallprävention mit dabigatran, rivaroxaban und apixaban. Herz, 40, 140-145.
